Free Trial
NASDAQ:MGNX

MacroGenics (MGNX) Stock Price, News & Analysis

MacroGenics logo
$1.62 -0.11 (-6.36%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$1.65 +0.03 (+1.79%)
As of 09/19/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MacroGenics Stock (NASDAQ:MGNX)

Advanced

Key Stats

Today's Range
$1.60
$1.75
50-Day Range
$1.44
$2.00
52-Week Range
$0.99
$5.10
Volume
923,220 shs
Average Volume
997,959 shs
Market Capitalization
$102.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.60
Consensus Rating
Moderate Buy

Company Overview

MacroGenics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

MGNX MarketRank™: 

MacroGenics scored higher than 89% of companies evaluated by MarketBeat, and ranked 112th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MacroGenics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

  • Upside Potential

    MacroGenics has a consensus price target of $3.60, representing about 122.2% upside from its current price of $1.62.

  • Amount of Analyst Coverage

    MacroGenics has only been the subject of 2 research reports in the past 90 days.

  • Read more about MacroGenics' stock forecast and price target.
  • Earnings Growth

    Earnings for MacroGenics are expected to decrease in the coming year, from ($1.06) to ($2.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MacroGenics is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MacroGenics is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MacroGenics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about MacroGenics' valuation and earnings.
  • Percentage of Shares Shorted

    6.48% of the float of MacroGenics has been sold short.
  • Short Interest Ratio / Days to Cover

    MacroGenics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MacroGenics has recently decreased by 3.59%, indicating that investor sentiment is improving.
  • Dividend Yield

    MacroGenics does not currently pay a dividend.

  • Dividend Growth

    MacroGenics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.48% of the float of MacroGenics has been sold short.
  • Short Interest Ratio / Days to Cover

    MacroGenics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MacroGenics has recently decreased by 3.59%, indicating that investor sentiment is improving.
  • News Sentiment

    MacroGenics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for MacroGenics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for MGNX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MacroGenics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $150,515.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    13.00% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MacroGenics' insider trading history.
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MGNX Stock News Headlines

Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
Brokerages Set MacroGenics, Inc. (NASDAQ:MGNX) Target Price at $3.60
William Heiden Bought 909% More Shares In MacroGenics
See More Headlines

MGNX Stock Analysis - Frequently Asked Questions

MacroGenics' stock was trading at $3.25 at the beginning of 2025. Since then, MGNX shares have decreased by 50.2% and is now trading at $1.62.

MacroGenics, Inc. (NASDAQ:MGNX) posted its earnings results on Thursday, August, 14th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.02. The biopharmaceutical company earned $22.24 million during the quarter, compared to analyst estimates of $28.06 million. MacroGenics had a negative net margin of 21.99% and a negative trailing twelve-month return on equity of 40.24%.

Top institutional investors of MacroGenics include Bellevue Group AG (15.72%), Armistice Capital LLC (9.45%), Acadian Asset Management LLC (3.95%) and EcoR1 Capital LLC (2.54%). Insiders that own company stock include Target N V Biotech, William K Heiden, Ezio Bonvini, Edward Hurwitz and Jeffrey Stuart Peters.
View institutional ownership trends
.

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include NVIDIA (NVDA), Broadcom (AVGO), Invesco QQQ (QQQ), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and Jabil (JBL).

Company Calendar

Last Earnings
8/14/2025
Today
9/22/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MGNX
CIK
1125345
Employees
430
Year Founded
2000

Price Target and Rating

High Price Target
$5.00
Low Price Target
$2.00
Potential Upside/Downside
+122.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$66.97 million
Net Margins
-21.99%
Pretax Margin
-21.36%
Return on Equity
-40.24%
Return on Assets
-14.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.26
Quick Ratio
5.02

Sales & Book Value

Annual Sales
$149.96 million
Price / Sales
0.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.85 per share
Price / Book
0.88

Miscellaneous

Outstanding Shares
63,210,000
Free Float
54,989,000
Market Cap
$102.40 million
Optionable
Optionable
Beta
1.63

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:MGNX) was last updated on 9/22/2025 by MarketBeat.com Staff
From Our Partners